Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2004

View Archived Issues

LifeSciChannel.com interviews Kalypsys at BIO-Europe 2004

Jak-Stat inhibitor shows promise for the treatment of AML

Toll-like receptor agonist may be an effective immunotherapeutic approach to CLL

Antibody therapy may enhance rituximab-mediated killing in non-Hodgkin's lymphoma

Bionomics receives START grant extension for breast cancer efforts

TS-041 enters phase I study

New conjugate carrier for effective antitumor boron neutron capture therapy

Medicis gains access to Ansata antimicrobial peptide technology

Axaminer demonstrates capabilities in studies

Vion updates phase II Triapine-gemcitabine study in pancreatic cancer

Procyon files IND for PCK-3145

Trillium and Genentech enter global license agreement

Abbott submits Xinlay NDA for metastatic hormone-refractory prostate

Aphton to acquire Igeneon

Aventis scientists prepare and test new oncolytic agents

Schering-Plough claims gamma-secretase inhibitors

Topical formulation for delivery of TRPVI agonists

Combination of CNS stimulant and opioid antagonist covered in Euroceltique patent

Pfizer researchers describe new renin inhibitors for hypertension

NicOx prepares for phase III program of HCT-3012

Two new series of muscarinic receptor antagonists designed at Ranbaxy

Brain tumor compound ECO-4601 enters pharmacology and toxicology trials

Retisert NDA accepted for review

Lunesta approved for treatment of insomnia

Zylet receives FDA approval

Phase III trial and other results for decitabine presented at ASH meeting

BMS-354825 demonstrates activity in resistant chronic myeloid leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...